100 Million Dollars for Juvenescence Rejuvenative Therapys
Jim Mellon, a billionaire biotechnologist investor who continues to drive a rejuvenation industry in biotech, is currently the talk of the town. Jim Mellon and his colleagues from Juvenescence announced that another $100M had been secured for the company. This money will be used to support and invest in promising biotech companies.
Juvenescence’s investment portfolio is diverse and includes companies with varying potential utility, depending on the point of view. They tend to favor small molecule drugs, which are more traditional. A few companies are particularly interesting.